Clinical trial NCT06729671: A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Official title: A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Psychosis
Keywords: microbiota
antipsychotic
weight gain
Lead sponsor: University College Cork
Sponsor class: OTHER
First posted: 2024-12-11
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression. Most antipsychotics are associated with significant weight gain and metabolic disturbances, which increase the risks for other diseases (obesity, diabetes, coronary diseases, etc.) and negatively impact medication adherence and quality of life. Evidence has shown that Olanzapine, for example, increases appetite, food intake, and food reward and modulates the gut microbiota. The gut microbiota can modulate adiposity, metabolism and immune-endocrine signals that impact host's energy balance and feeding behaviour. This, together with the fact that antipsychotic-induced remodelling of the gut microbiota has been associated with weight gain, suggests that microbiota-targeted interventions could help to alleviate or prevent the distressing side-effects of antipsychotic medications. The investigators have previously published promising data demonstrating anti-obesity effects of a novel Bifidobacterium longum APC1472, in a mouse model of obesity and in an overweight/obese population of humans, reducing levels of glucose and normalizing ghrelin levels. Because atypical antipsychotic medications are often used in people experiencing psychosis and the mechanisms of antipsychotic-induced weight gain and metabolic dysfunction have been suggested to include glucose intolerance (hyperglycaemia) and aberrant ghrelin signalling, the investigators propose to assess if adjunct supplementation of Bifidobacterium longum APC1472 can attenuate weight gain and metabolic side-effects associated with the use of atypical antipsychotic medication in people with non- affective psychosis. The investigators propose an exploratory patient-oriented research study, to assess the potential of adjunct Bifidobacterium longum APC1472 supplementation in individuals with psychosis receiving antipsychotic treatment, to ameliorate the liability to gain weight and/or normalize metabolic disturbances. Findings from this study will support clinical decision-making, increasing patient choice, and increase medication adherence, which will ultimately improve health and quality of life, and overall wellbeing of individuals as they pass through normal life stages.

Detailed description: Schizophrenia is a mental illness associated with psychosis and is treated with antipsychotic medication. These medications are very effective; however, they are associated with side-effects that impact people's physical health. Substantial body weight gain occurs in up to half of people during long-term antipsychotic treatment. Antipsychotics can also increase glucose (sugar) and lipid (fat) levels in the blood, and the ones that do this the most, tend to be the same ones that cause the most weight gain. People taking antipsychotics regard weight gain as one of the most distressing side-effects caused by their medication. This weight gain often leads people to stop taking their antipsychotic treatment with a risk of their psychosis returning. People with psychosis die 15-20 years earlier than the general population. The leading cause of 'years of life' lost in this population is poor physical health. Heart disease and metabolic disorders are 1.4-2-fold more common in this population. Being overweight increases the risk of heart attack, stroke, and developing many physical illnesses and cancers. Furthermore, being overweight and experiencing psychosis are associated with reduced self-esteem, reduced quality of life, and stigma.

In a previous study by the investigating team, the investigators found that a bacteria found in the gut of healthy individuals, Bifidobacterium longum APC1472, was able to prevent obesity in mice treated with an antipsychotic. A second study conducted by the investigating team with people who were overweight or obese found that this type of bacteria, which may be developed into a new probiotic, improved sugar levels. The investigators are now looking to examine the impact this bacteria could have on the weight, blood sugars, and wellbeing of people treated with antipsychotic medication. Having access to a probiotic capsule that alleviates the most distressing side-effects of antipsychotic medications will benefit people who need these medications greatly.

Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression. Most antipsychotics are associated with significant weight gain and metabolic disturbances, which increase the risks for other diseases (obesity, diabetes, coronary diseases, etc.) and negatively impact medication adherence and quality of life. Evidence has shown that olanzapine, for example, increases appetite, food intake, and food reward and modulates the gut microbiota. The gut microbiota can modulate adiposity, metabolism and immune-endocrine signals that impact host's energy balance and feeding behaviour. This, together with the fact that antipsychotics induced remodeling of the gut microbiota has been associated with weight gain, suggests that microbiota-targeted interventions could help to alleviate or prevent the distressing side-effects of antipsychotic medications. The investigators have previously published promising data demonstrating anti-obesity effects of a novel Bifidobacterium longum APC1472, in a mouse model of obesity and in an overweight/obese population of humans, reducing levels of glucose and normalizing ghrelin levels. Because atypical antipsychotic medications are often used in people experiencing psychosis and the mechanisms of antipsychotic-induced weight gain and metabolic dysfunction have been suggested to include glucose intolerance (hyperglycaemia) and aberrant ghrelin signalling, the investigators propose to assess if adjunct supplementation of Bifidobacterium longum APC1472 can attenuate weight gain and metabolic side-effects associated with the use of atypical antipsychotic medication in people with non- affective psychosis. The investigators propose an exploratory patient-oriented research study, to assess the potential of adjunct Bifidobacterium longum APC1472 supplementation in individuals with psychosis receiving antipsychotic treatment, to ameliorate the liability to gain weight and/or normalize metabolic disturbances. Findings from this study will support clinical decision-making, increasing patient choice, and increase medication adherence, which will ultimately improve health and quality of life, and overall wellbeing of individuals as they pass through normal life stages.

A high percentage of individuals experiencing affective or a non-affective psychotic episode are treated with second-generation antipsychotics. While effective, most are associated with a significant liability for weight gain and metabolic disorders, negatively impacting adherence, health and quality of life. This study will explore the potential of a metabolically beneficial Bifidobacterium longum APC1472 to attenuate weight gain and metabolic side-effects in individuals with a non-affective psychosis, treated with antipsychotics.

Eligibility criteria: Inclusion Criteria:

* 8.1 Inclusion Criteria To be considered eligible for enrolment into the study, subjects must;

  1. Aged between 18-65 years old including women of child-bearing age
  2. Having a diagnosis of affective or non-affective functional psychosis defined according to ICD-10 criteria for psychosis (codes F20-30 \& F32.3)
  3. Patients who are able to and have given written informed consent
  4. Patients who are willing to provide blood samples
  5. Patients who are willing to provide saliva (cortisol) and faecal microbiome samples
  6. Considering the nature of the study participants, a broad spectrum of concomitant medication will be permissible. Psychotropic meds, including antidepressants, mood stabilisers (lithium, valproate, carbamazepine), hypnotics and benzodiazapines, will be allowed as to not limit recruitment of this type of study participant.

Exclusion Criteria:

1. Intravenous drug use
2. Diagnosis of substance dependence in the past 3 months
3. Pregnancy or planning a pregnancy
4. Antibiotic use in the past 30 days
5. Steroid use in the past 30 days
6. Use of anti-coagulants, anti-inflammatory drugs, over-the counter non-steroidal anti-inflammatories (NSAIDS) and analgesics. Subjects should have a wash-out period of 4 weeks.
7. Patients suffering from any clinically significant or unstable medical condition, including congestive heart failure, coeliac disease, or an immunodeficiency syndrome.
8. Pre or probiotic supplements within the past 30 days.

Primary outcomes:
measure: Bifidobacterium longum on weight gain
timeFrame: change from baseline to 4, 8,12 weeks (end of study) and 18 weeks (washout)
measure: Bifidobacterium longum on glucose levels.
timeFrame: change from baseline to 4, 8, 12 weeks (end of study) and 18 weeks (washout)
Secondary outcomes:
measure: Bifidobacterium longum on waist-to-hip ratio
timeFrame: change from baseline to 4, 8, 12 weeks (end of study) and 18 weeks (washout)
measure: Bifidobacterium longum on metabolic syndrome markers
timeFrame: change from baseline to 4, 8, 12 weeks(end of study) and 18 weeks (washout)
measure: Bifidobacterium longum on cortisol awakening response
timeFrame: change from baseline to 4, 8, 12 weeks (end of study) and 18 weeks (washout)
measure: Bifidobacterium longum on treatment adherence
timeFrame: change from baseline to 4, 8, 12 weeks (end of study) and 18 weeks (washout)
measure: Bifidobacterium longum on changes in food intake behavior
timeFrame: change from baseline to 4,8, 12 weeks (end of study) and 18 weeks (washout)
Other outcomes:
measure: Bifidobacterium longum on neuroendocrine signalling
timeFrame: change from baseline to 4, 8, 12 weeks (end of study) and 18 weeks (washout)
measure: Bifidobacterium longum on inflammatory markers
timeFrame: change from baseline to 4, 8, 12 weeks (end of study) and 18 weeks (washout)
measure: Bifidobacterium longum on gut microbiota
timeFrame: change from baseline to 4, 8, 12 weeks (end of study) and 18 weeks (washout)
Locations:
city: Cork
country: Ireland
facility: EIST clinics at St Mary's Primary Care Centre, Gurraunabraher & St Michaels In-Patient unit in the Mercy.
city: Cork
country: Ireland
facility: RISE Metabolic Monitoring Clinics
Study officials:
affiliation: University College Cork
name: Harriet Schellekens, PhD
role: PRINCIPAL_INVESTIGATOR
References: